BiotechTube

Darolutamide (Nubeqa, BAY1841788)

Pre-clinicalRecruiting
0 views this week 0 watching💤 Quiet
Interest: 30/100
30
Hype Score

Development Stage

1
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Non-metastatic Castration-resistant Prostate Cancer

Conditions

Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer

Trial Timeline

Sep 25, 2024 → Jun 30, 2028

NCT ID
NCT06334120

About Darolutamide (Nubeqa, BAY1841788)

Darolutamide (Nubeqa, BAY1841788) is a pre-clinical stage product being developed by Bayer for Non-metastatic Castration-resistant Prostate Cancer. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06334120. Target conditions include Non-metastatic Castration-resistant Prostate Cancer, Metastatic Hormone-sensitive Prostate Cancer.

What happened to similar drugs?

1 of 6 similar drugs in Non-metastatic Castration-resistant Prostate Cancer were approved

Approved (1) Terminated (0) Active (5)
🔄Bicalutamide + PlaceboAstraZenecaPhase 3
🔄Bicalutamide + PlaceboAstraZenecaPhase 3
🔄Bicalutamide + PlaceboAstraZenecaPhase 3
🔄Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3
🔄Darolutamide (Nubeqa, BAY1841788) + PlaceboBayerPhase 3
✅Darolutamide (Nubeqa, BAY1841788)BayerApproved

Hype Score Breakdown

Clinical
3
Activity
15
Company
12
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT06334120Pre-clinicalRecruiting
NCT05348876ApprovedRecruiting
NCT04464226Phase 3Recruiting

Competing Products

14 competing products in Non-metastatic Castration-resistant Prostate Cancer

See all competitors
ProductCompanyStageHype Score
Bicalutamide + PlaceboAstraZenecaPhase 3
40
Gefitinib, radiotherapyAstraZenecaPhase 1/2
32
Bicalutamide + PlaceboAstraZenecaPhase 3
40
Gefitinib, 5-fluorouracil, leucovorin and radiotherapyAstraZenecaPhase 1/2
24
Bicalutamide + PlaceboAstraZenecaPhase 3
40
AvelumabMerckPhase 2
35
Doxorubicin + Ifosfamide or dacarbazine + Doxorubicin + Ifosfamide or dacarbazine + At the discretion of the investigatorNovartisPhase 3
47
HSP-130PfizerPhase 2
35
AK104 + LenvatinibAkesoPhase 2
39
Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + ApalutamideBayerPre-clinical
23
Darolutamide (Nubeqa, BAY1841788) + Enzalutamide + ApalutamideBayerPre-clinical
23
Darolutamide (Nubeqa, BAY1841788) + PlaceboBayerPhase 3
37
Darolutamide (Nubeqa, BAY1841788)BayerApproved
47
Apalutamide + Darolutamide (BAY 1841788) + EnzalutamideBayerPre-clinical
23